HS235 Study in Obese Participants With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF)

Part of paid clinical trials in Greenville, South Carolina.

Sponsor
35Pharma Inc
Study ID
NCT07123779
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • HS235 — BIOLOGICAL
    Subcutaneous Injection
  • Placebo — OTHER
    Subcutaneous Injection

Study Details

Study of HS235 in Obese Participants with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction

Key Dates

First listed
Aug 14, 2025
Start date
Aug 31, 2026
Status verified
Aug 2026
Primary completion
Jan 31, 2029
Completion
Jan 31, 2030

Study Design

Enrollment
126 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Investigational Product
    HS235 Subcutaneous Injection
  • Placebo Comparator: Placebo
    Subcutaneous Injection

Primary Outcome Measure

Incidence and Number of Adverse Events (AEs) [ Time Frame: Up to 24 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Investigational Site-101GreenvilleSouth Carolina29605-

Find similar trials in Greenville, SC

Nationwide
Heart failure trialsCardiology trialsHeart disease trials
By condition
Heart failure
By specialty
CardiologyHeart disease
By research site
Investigational Site-101· Greenville, SC

Related Studies